August 2009

Articles

THYROID DISORDERS

COVER STORY

DEPARTMENTS

View All News >
News
Endocrine Society Issues Response to Recently Published Insulin Glargine Studies

Five articles recently posted online in Diabetologia studied the possible connection between the use of insulin glargine [rDNA] injection (Lantus, Sanofi Aventis) and the development of cancer. One of these studies suggested ... more >

News
Long-Term Safety Results of Lantus Compared With NPH

The results of the long-term, 5-year study of insulin glargine (Lantus, Sanofi Aventis) versus neutral protamine Hagedorn (NPH) insulin on progression of retinopathy in patients with type 2 diabetes, published in Diabetologia show... more >

News
Takeda Receives FDA Complete Response Letter for Alogliptin

Takeda Pharmaceutical Company has received a complete response letter from the US Food and Drug Administration (FDA) regarding the new drug application (NDA) for alogliptin, a selective dipeptidyl peptidase IV inhibitor under inve... more >

News
Aliskiren Approved in Japan for Hypertension Treatment

The first-in-class renin inhibitor aliskiren (Rasilez, Tekturna), the first new type of high blood pressure medicine in more than a decade, has been approved for use in Japan. The Japanese Ministry of Health, Labour, and Welfare a... more >

TOP 5 ARTICLES FROM AUGUST 2009